Human blood

Tender description

NHSBT requires pathogen reduced plasma which will then be subsequently manufactured into FFP, Single and pooled cryoprecipitate for paediatric and neonatal use, for recipients born on/after 1.1.1996. Those recipients are deemed not to have been exposed to the risk of vCJD in the UK food chain. Plasma must be sourced from a country outside the UK with vCJD prevalence >2.5 log lower than the UK. The TPSG approved the following countries for supply of plasma based on SaBTO 2013: Australia, Austria, Canada, Finland, New Zealand, Norway, Poland, Sweden and the US. For other transfusion transmitted infections the final component risk must be ‘no worse than current’ (detailed in the component specification). The contract shall commence the date the contract is signed. The Term of the contract expires 2 years from the end of the Set Up Period. The Contract consists of a option to extend for 2 periods of 12 months. The Maximum Term of the Contract is 4 years from the end of the Set Up Period. NHS Blood and Transplant has a requirement to procure pathogen reduced plasma to be subsequently manufactured into components (fresh frozen plasma for paediatric and neonatal use, single and pooled cryoprecipitate for neonatal and paediatric use) for recipients born on or after 1.1.1996. Those recipients are deemed not to have been exposed to the risk of vCJD in the UK food chain and therefore plasma will be sourced from a country outside the UK with a vCJD prevalence > 2.5 log lower than the UK. The countries that are approved for the supply of plasma are Australia, Austria, Canada, Finland, New Zealand, Norway, Poland, Sweden and the United States (list approved by TPSG based on SaBTO report April 2013). Regarding other transfusion transmitted infections, the final component risk must be ‘no worse than current’ and is detailed within the component specification.